Glenmark announces discovery of new oncology molecule

Glenmark announces discovery of new oncology molecule Mumbai: Glenmark Pharmaceuticals on Thursday announced the discovery of a new molecule for oncology treatment and said it would file an application for phase-I trials in the fourth quarter of FY12. Developed at Glenmark’s Switzerland-based research centre, the GBR 401 molecule is an anti-CD19 monoclonal antibody primarily targeted for treating lymphoma and leukemia of B-cell origin, the drugmaker said in a statement. In addition, the molecule also has potential to treat disorders like rheumatoid arthritis, it added. The molecule is in the same segment of anti-cancer biotech product rituximab, which had annual global Read More


ˆ Back To Top